Reskuin en es it fr

Categoria

Reskuin Marchi, Reskuin Analoghi

Reskuin Marchi miscela

  • No information avaliable
  • Reskuin Formula chimica

    C36H42F2N6O9

    Reskuin RX link

    http://www.rxlist.com/cgi/generic2/quixin.htm

    Reskuin FDA foglio

    Reskuin FDA

    Reskuin DMS (foglio di materiale di sicurezza)

    Reskuin Sintesi di riferimento

    Mitscher, Lester A. et al,. J.Med.Chem;. 30, 12, 2283-2286 (1987)

    Reskuin Peso molecolare

    740.751 g/mol

    Reskuin Temperatura di fusione

    No information avaliable

    Reskuin H2O Solubilita

    Insolubile

    Reskuin Stato

    Solid

    Reskuin LogP

    1.268

    Reskuin Forme di dosaggio

    Compressa, liquidi; Soluzione

    Reskuin Indicazione

    Per il trattamento della congiuntivite batterica causata da ceppi sensibili dei seguenti organismi: specie Corynebacterium, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, , Streptococcus (Gruppi C / F / G), gli streptococchi del gruppo viridans, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

    Reskuin Farmacologia

    Levofloxacina, un fluorochinolone antinfettivo, è otticamente attivo L-isomero di ofloxacina. Levofloxacina è usato per trattare la congiuntivite batterica, sinusite, bronchite cronica, polmonite acquisita in comunità e polmonite causata da ceppi resistenti alla penicillina di Streptococcus pneumoniae, infezioni della struttura della pelle e della pelle, infezioni complicate delle vie urinarie e pielonefrite acuta.

    Reskuin Assorbimento

    L'assorbimento di ofloxacina dopo dosi singole o multiple da 200 a 400 mg è prevedibile, e la quantità di farmaco assorbita aumenta proporzionalmente con la dose.

    Reskuin Tossicita

    Gli effetti collaterali includono disorientamento, vertigini, sonnolenza, vampate di calore e di freddo, nausea, impastando di parola, gonfiore e intorpidimento del viso

    Reskuin Informazioni paziente

    PATIENT INFORMATION

    While taking ofloxacin patient should be advised to:

    � to drink fluids liberally;

    � that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;

    � that ofloxacin can be taken without regard to meals;

    � that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;

    � to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;

    � that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction

    � to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;

    � that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;

    � that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.

    Reskuin Atto interessato organismi

    Batteri enterici e altri eubatteri